Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Blood
|
June 20, 2015
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Garyfalia Karponi, Nikoletta Psatha, Carsten Werner Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos, Athanasios Anagnostopoulos, Marie-Christine Kyrtsonis, et al.
European Journal of Haematology
|
April 4, 2012
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era
Meletios A Dimopoulos, Efstathios Kastritis, Sossana Delimpasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2015
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Paraskevi Miltiades, Eleftheria Lamprianidou, Theodoros P Vassilakopoulos, et al.
Leukemia Research
|
May 8, 2010
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)
Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, et al.
Haematologica
|
January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease
Theodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Blood
|
June 20, 2015
Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy
Garyfalia Karponi, Nikoletta Psatha, Carsten Werner Lederer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2007
Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos, Athanasios Anagnostopoulos, Marie-Christine Kyrtsonis, et al.
European Journal of Haematology
|
April 4, 2012
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era
Meletios A Dimopoulos, Efstathios Kastritis, Sossana Delimpasi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2015
The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Paraskevi Miltiades, Eleftheria Lamprianidou, Theodoros P Vassilakopoulos, et al.
Leukemia Research
|
May 8, 2010
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)
Efstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hadjiharissi, et al.
Haematologica
|
January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease
Theodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Page
of 2